HomeNewsBusinessMarketsFor the time being, 7,511 can be taken as a bottom in the intermediate-term: Umesh Mehta

For the time being, 7,511 can be taken as a bottom in the intermediate-term: Umesh Mehta

April may turn out to be a sucker’s rally where the fence-sitters will be pulled in. We will see some amount of price stabilizing but a major rally to go past 10,000 on the Nifty is less likely.

March 29, 2020 / 16:15 IST
Story continues below Advertisement

April will most likely be a "wait and watch" period. It can close in positive since the markets are deep in the oversold zone, but for the time being, 7,511 can be taken as a bottom in the intermediate-term, Umesh Mehta, Head of Research, Samco Securities, said in an interview with Moneycontrol’s Kshitij Anand.

edited excerpts:

Story continues below Advertisement

Q) It was a volatile week for Indian markets, but the good part is we managed to bounce back from 7,511 thanks to the various fiscal measures taken by the government and authorities around the world. What is your take on the market action?

A) In October 2008 when the US Fed had announced a stimulus package, markets rebounded for some time, but thereafter the slide continued. Price destruction was lesser post the stimulus package.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show